APR Sept/Oct 2023 - 118

»
SECTION TITLE
»
Pharmaceutical
P.I.N.
Points
Patent Innovation News
Article Title
The purpose of this column is to highlight
and summarize recent key patents in the
pharmaceutical arena issued by the US
Patent Office in June-July, 2023.
Neelam Sharma, MS,
Lakshmi Lavanya Kundurthy, BE and
Hemant N. Joshi, Ph.D., MBA*
Tara Innovations, LLC
www.tara-marketing.com,
*hemantjoshi@tarainnovations.com
Introduction
Paragrapgh Text
Echovirus for Treatment of Tumors;
C. Tong, W. Wang, J. Wan, L. Xu, X. Ye, J.
Zhang and N. Xia; Xiamen University and
Yang Sheng Tang Company Ltd., China;
U.S. Patent # 11,707,496; July 25, 2023.
Current methods like surgery, chemotherapy and radiotherapy
can help cancer patients but may also cause great harm to the
health of patients. The emergence of oncolytic viruses provided a
new therapy to possibly cure malignant tumors. An oncolytic virus
can be described as a genetically engineered or naturally existing
virus that can selectively replicate in cancer cells and then kill
them without damaging the healthy cells. Enteroviruses are one of
kind of oncolytic viruses. The inventors of the present application
found that Echovirus 25 has significant tumor cell killing ability for
specific tumors. The present patent discloses use of an Echovirus
25 (ECHO25) or a modified form thereof, or a nucleic acid molecule
comprising a genomic sequence or cDNA sequence of the ECHO25.
Tri-Specific Binding Molecules
that Specifically Bind to
Multiple Cancer Antigens;
E. Bonvini, P.A. Moore, J. C. Li, L.S.
Johnson and K. Shah; Macrogenics
Inc., USA; U.S. Patent # 11,697,684;
July 11, 2023.
The present invention relates to Tri-Specific Binding
Molecules, which are multi-chain polypeptide molecules
that possess three Binding Domains. These are capable
of mediating coordinated binding to three epitopes - (1)
an epitope of a first Cancer Antigen, (2) an epitope of a
second Cancer Antigen, and (3) an epitope of a molecule
that is expressed on the surface of an immune system
effector cell. This immune-specific binding is capable of
localizing an immune system effector cell to a cell that
expresses a Cancer Antigen, so as to thereby facilitate
the killing of such cancer cell. Generally, the ingredients
of compositions of the invention are supplied either
separately or mixed together in unit dosage form.
Author Name
Author Title
Author Company
Factory-on-a-Chip for Production
of Biologically Derived Medicines/
Biopharmaceuticals/Biologics/
Biotherapeutics;
G. Rao, Y. Kostov, A. Andar, M.Al-Adhami,
S. Deldari, and D. D. Frey; University of Maryland,
USA: U.S. Patent # 11,708,553; July 25, 2023.
Production of biotherapeutics involves a large-scale process chain, which
includes large volume separation, purification, formulation, packaging
and distribution. To counter the complexities and expense, maintain living
organisms, and reduce production time, recent efforts have seen the use
of cellular extracts as a source for biomanufacturing. The present invention
provides for a fully integrated microfluidic system capable of producing
single-dose amounts of biotherapeutics at the point-of-care wherein
protein production, purification and product harvest are all integrated as
a single microfluidic device, which is portable and capable of continuousflow
production of biotherapeutics at the microscale using a cell-free
reaction system. It has a portable " factory-on-a-chip " comprising three
primary components. (i) a microfluidic bioreactor unit for synthesizing
a crude protein, (ii) a microfluidic mixer/de-bubbler unit connected
to the bioreactor unit to dilute the crude protein and remove any air
bubbles during mixing; (iii) a microfluidic purification unit has at least one
purification column to provide the purified protein. This integrated device
comprising a reactor, mixer and purification chip is connected together as
one platform chip.
118 |
| November/December 2021
September/October 2023
http://www.tara-marketing.com
APR Sept/Oct 2023

Table of Contents for the Digital Edition of APR Sept/Oct 2023
